Patents by Inventor Mor ORON-HERMAN
Mor ORON-HERMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827687Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: February 3, 2022Date of Patent: November 28, 2023Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmilla Buzhansky
-
Publication number: 20220162284Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: February 3, 2022Publication date: May 26, 2022Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmilla BUZHANSKY
-
Patent number: 11261230Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: June 28, 2020Date of Patent: March 1, 2022Assignees: RAMOT AT TEL AVIV UNIVERSITY LTD., TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20210338119Abstract: Some embodiments are directed to a system and method monitoring oxygenation in biological tissue, comprising a control unit configured and operable to receive data indicative of light response from a region of the biological tissue being subjected to illumination and/or collection at two separate wavelengths in two selected wavelength ranges and processing the data by comparing data indicative of each selected wavelength range to determine an oxygenated/deoxygenated status of the biological tissue. The two wavelength ranges include a first wavelength range in which the absorbance of the deoxyhemoglobin within the tissue is higher than the oxyhemoglobin, and a second wavelength range in which the absorbance of the oxyhemoglobin within the tissue is higher than the deoxyhemoglobin or vice versa. The two wavelengths in the two wavelength ranges include first and second wavelengths satisfying a predetermined condition of a ratio between the absorbance of the deoxyhemoglobin and oxyhemoglobin for each wavelength.Type: ApplicationFiled: August 27, 2019Publication date: November 4, 2021Inventors: Genady KOSTENICH, Arie ORENSTEIN, Mor ORON-HERMAN
-
Publication number: 20200325203Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: June 28, 2020Publication date: October 15, 2020Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 10723780Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: March 19, 2019Date of Patent: July 28, 2020Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20190276513Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: March 19, 2019Publication date: September 12, 2019Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY
-
Patent number: 10266579Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: GrantFiled: September 10, 2015Date of Patent: April 23, 2019Assignees: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Genady Kostenich, Mor Oron-Herman, Arie Orenstein, Talia Shekhter Zahavi, Ehud Gazit, Yoseph Salitra, Ludmila Buzhansky
-
Publication number: 20170298113Abstract: Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.Type: ApplicationFiled: September 10, 2015Publication date: October 19, 2017Inventors: Genady KOSTENICH, Mor ORON-HERMAN, Arie ORENSTEIN, Talia SHEKHTER ZAHAVI, Ehud GAZIT, Yoseph SALITRA, Ludmila BUZHANSKY